BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27247367)

  • 1. Assessment of Melanocyte Density in Anorectal Mucosa for the Evaluation of Surgical Margins in Primary Anorectal Melanoma.
    Tse JY; Chan MP; Zukerberg LR; Nazarian RM
    Am J Clin Pathol; 2016 May; 145(5):626-34. PubMed ID: 27247367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of MITF and Melan-A Immunohistochemistry During Mohs Surgery for Lentigo Maligna-Type Melanoma In Situ and Lentigo Maligna Melanoma.
    Christensen KN; Hochwalt PC; Hocker TL; Roenigk RK; Brewer JD; Baum CL; Otley CC; Arpey CJ
    Dermatol Surg; 2016 Feb; 42(2):167-75. PubMed ID: 26771682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anorectal Melanoma - a Histopathological Case Report and a Review of the Literature.
    Kobakova I; Stoyanov G; Popov H; Spasova-Nyagulova S; Stefanova N; Stoev L; Yanulova N
    Folia Med (Plovdiv); 2018 Dec; 60(4):641-646. PubMed ID: 31188769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
    Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
    Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary anorectal mucosal melanoma detected by anorectal cytology.
    Lau RP; Chiaffarano J; Alexander M; Octavius J; Azar O; Shi Y; Yee-Chang M
    Diagn Cytopathol; 2017 May; 45(5):452-455. PubMed ID: 28160456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
    Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid frozen section immunostaining of melanocytes by microphthalmia-associated transcription factor.
    Glass LF; Raziano RM; Clark GS; Higgins HW; Ladd S; Lien MH; Chen R; Cherpelis BS
    Am J Dermatopathol; 2010 Jun; 32(4):319-25. PubMed ID: 20514666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of MiTF staining in undifferentiated pleomorphic sarcoma: caution in the use of melanocytic markers in sarcoma.
    Choy B; Hyjek E; Montag AG; Pytel P; Haydon R; Luu HH; Zhen CJ; Long BC; Kadri S; Segal JP; Furtado LV; Cipriani NA
    Histopathology; 2017 Apr; 70(5):734-745. PubMed ID: 27926791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
    McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
    Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
    Thiel A; Moza M; Kytölä S; Orpana A; Jahkola T; Hernberg M; Virolainen S; Ristimäki A
    Hum Pathol; 2015 Feb; 46(2):169-75. PubMed ID: 25442222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of MITF, SOX10, MART-1, and R21 Immunostaining for the Diagnosis of Residual Melanoma In Situ on Chronically Sun-Damaged Skin.
    Mu EW; Quatrano NA; Yagerman SE; Ratner D; Meehan SA
    Dermatol Surg; 2018 Jul; 44(7):933-938. PubMed ID: 29419543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is melanocyte density our last hope? Comparison of histologic features of photodamaged skin and melanoma in situ after staged surgical excision with concurrent scouting biopsies.
    Speiser J; Tao J; Champlain A; Moy L; Janeczek M; Omman R; Mudaliar K; Tung R
    J Cutan Pathol; 2019 Aug; 46(8):555-562. PubMed ID: 30903709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
    Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
    Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.